4/20
04:03 pm
cmnd
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
High
Report
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
4/20
07:15 am
cmnd
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
High
Report
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
4/15
07:30 am
cmnd
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
High
Report
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
4/14
07:32 am
cmnd
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
High
Report
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
3/30
08:45 am
cmnd
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder [Yahoo! Finance]
High
Report
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder [Yahoo! Finance]
3/30
08:32 am
cmnd
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
High
Report
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
3/27
07:32 am
cmnd
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
High
Report
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
3/19
08:45 am
cmnd
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
Medium
Report
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
3/17
10:13 am
cmnd
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies [Yahoo! Finance]
Low
Report
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies [Yahoo! Finance]
3/17
09:15 am
cmnd
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
Low
Report
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
3/13
08:09 am
cmnd
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy [Yahoo! Finance]
Low
Report
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy [Yahoo! Finance]
3/13
07:45 am
cmnd
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
High
Report
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
3/11
09:27 am
cmnd
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results [Yahoo! Finance]
High
Report
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results [Yahoo! Finance]
3/11
09:07 am
cmnd
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
High
Report
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
3/10
08:59 am
cmnd
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Medium
Report
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
3/4
07:51 am
cmnd
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval [Yahoo! Finance]
Medium
Report
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval [Yahoo! Finance]
3/4
07:30 am
cmnd
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
High
Report
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
2/19
01:05 pm
cmnd
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
Medium
Report
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
2/9
08:17 am
cmnd
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
High
Report
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
2/6
07:55 am
cmnd
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
High
Report
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
2/3
08:00 am
cmnd
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
High
Report
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
1/20
06:21 pm
cmnd
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 [Yahoo! Finance]
Low
Report
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 [Yahoo! Finance]
1/20
04:20 pm
cmnd
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
Medium
Report
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025